An Updated Review on Repurposing of Metformin DOI Open Access

Hind A Rikabi,

Dalia A. Abdulla,

Mahmoud M. E. Mudawi

et al.

Asian Journal of Pharmaceutical Research and Health Care, Journal Year: 2024, Volume and Issue: 16(4), P. 344 - 351

Published: Oct. 1, 2024

A BSTRACT Even with the swift progress in scientific understanding of various diseases such as cancer, cardiovascular diseases, and diabetes, there remains a need for effective new treatments. Now, other drug development strategies, repurposing existing medicines to treat which will save time money, are being investigated. Since metformin is one most used drugs worldwide it investigated uses, therefore, this review potential uses beyond its established use diabetes highlighted several polycystic ovary syndrome (PCOS), weight reduction, lowering plasma lipids, delaying aging process, possible role reducing mortality pandemic COVID-19. An extensive literature search was conducted on PubMed Google Scholar databases identify relevant literature.

Language: Английский

Ovarian Aging: The Silent Catalyst of Age-Related Disorders in Female Body DOI Creative Commons
Xingyu Liu, Yu Zhao,

Yanzhi Feng

et al.

Aging and Disease, Journal Year: 2025, Volume and Issue: unknown, P. 0 - 0

Published: Jan. 1, 2025

Age-related diseases have emerged as a global concern the population ages. Consequently, understanding underlying causes of aging and exploring potential anti-aging interventions is imperative. In females, ovaries serve principal organs responsible for ovulation production female hormones. The are related to infertility, menopause, associated menopausal syndromes, with menopause representing culmination ovarian aging. Current evidence indicates that may contribute dysfunction across multiple organ systems, including, but not limited to, cognitive impairment, osteoporosis, cardiovascular disease. Nevertheless, due widespread distribution sex hormone receptors throughout body, affects only these specific also influences broader spectrum age-related in women. Despite this, impact on overall has been largely neglected. This review provides thorough summary diseases, encompassing nervous, circulatory, locomotor, urinary, digestive, respiratory, endocrine systems. Additionally, we outlined prospective therapeutic approaches addressing both aim mitigating their impacts preserving women's fertility, physical health, psychological well-being.

Language: Английский

Citations

1
Repurposing of Metabolic Drugs Metformin and Simvastatin as an Emerging Class of Cancer Therapeutics DOI Creative Commons
Santosh K. Maurya,

Smriti Chaudhri,

Shashank Kumar

et al.

Pharmaceutical Research, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 7, 2025

Language: Английский

Citations

0
Comparison of GLP-1 Receptor Agonists Combined with Metformin Versus Metformin Alone in the Management of PCOS: A Comprehensive Meta-Analysis DOI

Yuzi Zhao,

Jiang Li,

Na Li

et al.

Reproductive Sciences, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 29, 2025

Language: Английский

Citations

0
Inhibition of hepatic gluconeogenesis in type 2 diabetes by metformin: complementary role of nitric oxide DOI
Azam Shirinabadi Farahani,

Aryan Farahani,

Khosrow Kashfi

et al.

Medical Gas Research, Journal Year: 2025, Volume and Issue: 15(4), P. 507 - 519

Published: April 29, 2025

Metformin is the first-line treatment for type 2 diabetes mellitus. Type mellitus associated with decreased nitric oxide bioavailability, which has significant metabolic implications, including enhanced insulin secretion and peripheral glucose utilization. Similar to metformin, also inhibits hepatic production, mainly by suppressing gluconeogenesis. This review explores combined effects of metformin on gluconeogenesis proposes potential a hybrid metformin-nitric drug managing Both inhibit through overlapping distinct mechanisms. In gluconeogenesis, mitochondrial oxaloacetate exported cytoplasm via various pathways, malate, direct, aspartate, fumarate pathways. The exportation are complementary; primarily malate pathway, while strongly aspartate Furthermore, effectively blocks from lactate, glycerol, glutamine, whereas alanine-induced Additionally, contributes adenosine monophosphate-activated protein kinase-dependent inhibition induced metformin. use offers mitigate common side effects. For example, lactic acidosis, known effect linked deficiency, oxidative nitrosative stress caused could be counterbalanced metformin’s enhancement glutathione. amplifies -induced activation kinase. conclusion, can benefit patients enhancing decreasing required dose maintaining optimal glycemia, lowering incidence metformin-associated acidosis.

Language: Английский

Citations

0
Comparison of Metformin and Metformin Plus Liraglutide for Treating Metabolic Syndrome in Patients with Polycystic Ovarian Syndrome (PCOS) DOI

Yousra Naz,

Zeryab Setna,

Sabiha Banu

et al.

Indus journal of bioscience research., Journal Year: 2025, Volume and Issue: 3(3), P. 238 - 243

Published: March 18, 2025

Background: This study compares the effectiveness of metformin (MET) monotherapy versus a combination MET and liraglutide (LIRA) in managing metabolic syndrome overweight women with polycystic ovary (PCOS), focusing on weight reduction body mass index (BMI). Methods: A prospective cohort was conducted at Lady Dufferin Hospital, Karachi from April 2024 to Oct 2024, involving 70 aged 18–40 years, diagnosed PCOS based Rotterdam criteria, having BMI ≥ 27.5 kg/m². Participants were randomly assigned into two groups: Group received (1500 mg/day), B mg/day) plus LIRA (1.2 for 12 weeks. Baseline post-treatment outcomes, including weight, BMI, waist circumference, lipid profiles, analyzed. Results: Both treatment regimens significantly improved parameters. demonstrated superior results an average loss 10.30 ± 1.30 kg 3.72 0.67, compared A’s 5.99 2.87 2.24 1.07 (p < 0.001). Improvements triglyceride levels, HDL cholesterol, circumference more pronounced B. However, no significant changes hypertension parameters observed either group. Conclusion: The is effective than patients. dual therapy offers enhanced benefits, potentially improving both reproductive overall health. Further long-term, multicenter studies are warranted explore its broader impacts sustainability.

Language: Английский

Citations

0
Pharmacokinetics and Safety of a Fixed‐Dose Combination of Alogliptin and Extended‐Release Metformin Under Fasting and/or Fed Conditions in Healthy Adults DOI
Ji Hye Song, Jae‐Hoon Kim, Jang Hee Hong

et al.

Clinical Pharmacology in Drug Development, Journal Year: 2025, Volume and Issue: unknown

Published: April 16, 2025

Abstract This phase 1, randomized, open‐label, 2 × crossover study evaluated the bioequivalence of fixed‐dose combination (FDC) formulations alogliptin (ALO) and metformin extended‐release (MET XR) compared to their individual assessed effect food on FDC pharmacokinetics in healthy participants. The comprised high‐dose (ALO 25 mg/MET XR 1000 mg) low‐dose 12.5 500 mg), both conducted under fasting conditions, fed conditions. Among enrolled participants, 46 50 completed study, 45 51 22 26 study. Plasma concentrations were analyzed using liquid chromatography‐tandem mass spectrometry. geometric mean ratios AUC last C max for versus within range (0.80‐1.25) ALO MET XR. ALO's unaffected by food, while exhibited a significant effect, with increasing factor 1.63 T delayed hours. Given these findings, should be administered consistent monotherapy recommendations.

Language: Английский

Citations

0
Impact of Different Anti-Hyperglycaemic Treatments on Bone Turnover Markers and Bone Mineral Density in Type 2 Diabetes Mellitus Patients: A Systematic Review and Meta-Analysis DOI Open Access

Md Sadman Sakib Saadi,

Rajib Das, Adhithya Mullath Ullas

et al.

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(14), P. 7988 - 7988

Published: July 22, 2024

Diabetic bone disease (DBD) is a frequent complication in patients with type 2 diabetes mellitus (T2DM), characterised by altered mineral density (BMD) and turnover marker (BTMs) levels. The impact of different anti-diabetic medications on the skeleton remains unclear, studies have reported conflicting results; thus, need for comprehensive systematic review paramount importance. A search was conducted PubMed Cochrane Library. primary outcomes assessed were changes BMD relation to anatomical sites BTMs, including mainly P1NP CTX as well OPG, OCN, B-ALP RANK-L. Risk bias evaluated using JADAD score. meta-analysis 19 randomised controlled trials comprising 4914 showed that overall increased at lumbar spine (SMD: 0.93, 95% CI [0.13, 1.73], p = 0.02), femoral neck 1.10, [0.47, 1.74], 0.0007) total hip 0.33, [-0.25, 0.92], 0.27) comparison placebo, but when compared metformin, effect favoured metformin over other treatments -0.23, [-0.39, -0.07], 0.004). GLP-1 receptor agonists insulin analogues seem improve while SGLT2 inhibitors thiazolidinediones (TZDs) no significant effect, although studies' number cannot lead safe conclusions. For TZDs significantly levels placebo. However, differences observed CTX, B-ALP, RANK-L between drugs or High heterogeneity diverse follow-up durations among evident, which obscures validity results. This highlights variable effects DBD T2DM patients, emphasising long-term robust designs better understand these relationships inform clinical decisions.

Language: Английский

Citations

3
Metformin administration during pregnancy tends to reduce the risk of gestational diabetes mellitus and improve pregnancy outcomes in previously infertile women with polycystic ovary syndrome who become pregnant DOI
H. Liu,

Y Liu,

Changhe Wei

et al.

Irish Journal of Medical Science (1971 -), Journal Year: 2024, Volume and Issue: unknown

Published: July 20, 2024

Language: Английский

Citations

1
Metformin-associated lactic acidosis and mortality in type 2 diabetes patients hospitalized with heart failure and/or acute coronary syndrome: A neglected clinical scenario and the potential role of insulin DOI
Chin‐Hsiao Tseng

International Journal of Cardiology, Journal Year: 2024, Volume and Issue: 414, P. 132400 - 132400

Published: July 31, 2024

Language: Английский

Citations

1
Metformin-mediated effects on mesenchymal stem cells and mechanisms: proliferation, differentiation and aging DOI Creative Commons
Xinjuan Liu, Zekun Li,

Luyun Liu

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 15

Published: Aug. 13, 2024

Mesenchymal stem cells (MSCs) are a type of pluripotent adult cell with strong self-renewal and multi-differentiation abilities. Their excellent biological traits, minimal immunogenicity, abundant availability have made them the perfect seed for treating wide range diseases. After more than 60 years clinical practice, metformin is currently one most commonly used hypoglycaemic drugs 2 diabetes in practice. In addition, has shown great potential treatment various systemic diseases except recent years, mechanisms involved antioxidant stress, anti-inflammatory, induced autophagy, etc. This article reviews effects underlying on properties, including proliferation, multi-differentiation, aging, MSCs vitro vivo aim providing theoretical support in-depth scientific research applications MSCs-mediated disease treatment.

Language: Английский

Citations

1